Avelumab Monotherapy
Indication
00535a
Treatment of adult patients with metastatic Merkel cell carcinoma who have received 1 or more lines of chemotherapy for metastatic disease
Cemiplimab Therapy
Indication
00812b
As monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation
Cobimetinib and Vemurafenib Therapy
Indication
00373a
Cobimetinib in combination with vemurafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Dabrafenib Monotherapy
Indication
00237a
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Dacarbazine Therapy
Encorafenib and Binimetinib Therapy
Indication
00563a
Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation
Ipilimumab Monotherapy
Nivolumab Monotherapy - 14 day
Indication
00483a
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.
00483f
As monotherapy for the adjuvant treatment of adults with melanoma withinvolvement of lymph nodes or metastatic disease who have undergonecomplete resection
Nivolumab Monotherapy - 28 day
Indication
00484a
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.
00484c
As monotherapy for the adjuvant treatment of adults with melanoma with
involvement of lymph nodes or metastatic disease who have undergone complete resection
Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy
Indication
00431a
Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults
Nivolumab 3mg/kg Ipilimumab 1mg/kg Therapy
Indication
00551b
Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults
Pembrolizumab 200mg Monotherapy
Indication
00455b
As monotherapy for the treatment of adults with unresectable or advanced melanoma
00455c
For the treatment of ipiplimumab-refractory patients with unresectable or advanced metastatic melanoma.
00455g
As monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection
00455l
As monotherapy for the adjuvant treatment of adults with Stage IIB or IIC melanoma and who have undergone complete resection.
Pembrolizumab 400 mg Monotherapy
Indication
00558b
As monotherapy for the treatment of adults with unresectable or advanced melanoma
00558c
For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma
00558g
As monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection
00558l
As monotherapy for the adjuvant treatment of adults with Stage IIB or IIC melanoma and who have undergone complete resection.
Trametinib and Dabrafenib Therapy
Indication
00415a
Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Vemurafenib Monotherapy
Indication
00102a
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
Vismodegib Monotherapy
Indication
00236a
Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC)
00236b
Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.